6:02 PM
 | 
Dec 13, 2012
 |  BC Extra  |  Politics & Policy

FDA: holding meetings, but no biosimilar applications yet

FDA told BioCentury the agency has not received any applications for biosimilars under the 351(k) pathway, which was signed into law in 2010 as part of the Patient Protection and Affordability Act. As of Dec....

Read the full 155 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >